Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin (AMRN) reported third-quarter 2026 net income of $0.2 million, returning to profitability as operating expenses fell from a year earlier. Revenue declined 20% to $39.6 million, while operating expenses fell 44% to $18.5 million. The operating loss narrowed to $2.4 million from $11.1 million; net income compared with a $7.7 million loss.
U.S. product revenue fell 30% to $28.5 million, largely reflecting lower net pricing amid generic competition. Estimated partner-market demand grew 55% year over year, including 68% growth in Europe. Operating cash flow reached $9.2 million, and cash, cash equivalents and short-term investments totaled $323.4 million, with no debt. Amarin expects approximately $330 million in those liquid assets at year-end and positive fourth-quarter operating cash flow. For the first nine months, revenue fell 23% to $126.9 million and the net loss narrowed to $17.9 million from $37.6 million.
Amarin (AMRN) reported mixed Phase 3 EMT2 results for icosapent ethyl in patients undergoing surgery for colorectal cancer liver metastases. The University of Leeds-sponsored trial missed its primary endpoint of progression-free survival, the time before cancer progresses or death occurs: median results were 13.5 months versus 12.9 months with placebo (p=0.329).
The key secondary endpoint, overall survival, showed a statistically significant benefit. Estimated five-year survival was 62.0% versus 45.1%, corresponding to an approximately 32% reduction in death risk (adjusted hazard ratio 0.68; p=0.030). Both analyses included all randomized patients. There was no excess of total or serious adverse events, atrial fibrillation, bleeding episodes or clinically meaningful quality-of-life deterioration versus placebo. Amarin plans to collaborate with the sponsor to better understand the results and assess the potential opportunity.
Amarin (NASDAQ: AMRN) will report third quarter 2026 financial results and host a conference call on October 28, 2026. Results will be released before the market opens, followed by a call with senior management at 8:00 a.m. ET. A live webcast will be available through the company's Investor Relations website.
Amarin (NASDAQ: AMRN) reported multiple new REDUCE-IT and mechanistic findings presented at ESC Congress 2026 in Munich, focused on treatment adherence, long-term outcomes, lipoprotein(a) [Lp(a)], coagulation biomarkers and pathways related to eicosapentaenoic acid (EPA) and icosapent ethyl (IPE).
Post hoc REDUCE-IT analyses described substantial variability in Lp(a) over 24 months, sex differences in study discontinuation, and reductions in tissue factor levels plus lower first cardiovascular event risk with icosapent ethyl in high-risk patients with elevated baseline tissue factor. Mechanistic work showed EPA limited Lp(a) oxidation and favorably modulated endothelial cell protein expression. Amarin also highlighted that new 2026 ESC/European Renal Association guidelines for cardiovascular disease and chronic kidney disease cite REDUCE-IT RENAL, reinforcing support for icosapent ethyl in statin-treated patients with elevated triglycerides and chronic kidney disease.
Amarin (NASDAQ:AMRN) reported new post hoc “REDUCE-IT Legacy” data presented at ESC Congress 2026, based on the REDUCE-IT® cardiovascular outcomes trial of 8,179 statin-treated, high‑risk patients with elevated triglycerides. Among 6,921 “high adherers” who stayed on icosapent ethyl (IPE) for at least 1.5 years, investigators observed approximately 29–30% relative risk reduction in the primary composite endpoint versus placebo, compared with 25% in the intention‑to‑treat population.
In a secondary prevention cohort of 1,318 patients who discontinued study drug after a mean 2.3 years, Kaplan‑Meier curves remained separated with a hazard ratio of 0.73 during total follow‑up and 0.73 after discontinuation, suggesting a potential “legacy” effect with no apparent loss of benefit over one to four years off therapy.
Amarin (NASDAQ: AMRN) announced multiple upcoming scientific presentations at the European Society of Cardiology (ESC) Congress 2026, held August 28–31 in Munich, Germany. The accepted abstracts expand evidence from the REDUCE-IT cardiovascular outcomes trial and related mechanistic research on icosapent ethyl/eicosapentaenoic acid (EPA).
Amarin-supported academic collaborators will present moderated posters on treatment adherence and “legacy” effects of high-dose EPA in high-risk patients, sex differences in early study discontinuation and drug withdrawal in REDUCE-IT, and post hoc analyses of coagulation biomarkers and their association with event-free survival. Additional work will examine how EPA influences oxidation of lipoprotein(a) [Lp(a)] and endothelial protein expression.
An oral presentation will address Lp(a) variability in high cardiovascular risk, hypertriglyceridemic patients on statins within REDUCE-IT. The release reiterates REDUCE-IT design, key VASCEPA/VAZKEPA indications, global approvals, and important U.S. safety information, including atrial fibrillation and bleeding risks.
Amarin (NASDAQ: AMRN) reported Q2 2026 total net revenue of $42.2 million, down 42% year over year, mainly due to the absence of the prior-year $25 million Recordati upfront payment and lower U.S./European product revenue under the partnered model. Net product revenue was $39.1 million, down 16%.
Operating expenses fell to $27.0 million (‑59%), or 38% lower excluding Q2 2025 restructuring, completing a $70 million annual cost-savings plan. Net loss improved to $7.7 million from $14.1 million, with operating margin at ‑28%. Cash increased to $314.6 million and the company remained debt-free, generating positive cash flow for the third straight quarter and targeting ~10% cash growth for full-year 2026.
Across partners, in‑market VASCEPA/VAZKEPA demand rose 59% year over year, with Europe up 69% and China in‑market volume up 90% year-to-date. U.S. IPE market share increased to 48% from 43%, with branded VASCEPA prescriptions up 14%. Amarin expects continued international growth, stable 2026 U.S. volumes, an improved operating expense profile and positive cash flow.
Amarin (NASDAQ: AMRN) will release its Q2 2026 financial results on Wednesday, July 29, 2026, in pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Investors can access the live call via U.S. dial-in 888-506-0062, international dial-in 973-528-0011 (access code 444188), or through a webcast on the Investor Relations section of Amarin's website.
A replay will be available by telephone at 877-481-4010 (U.S.) or 919-882-2331 (international), using replay code 54179, and via webcast replay on the Investor Relations section of the company's website until January 29, 2027.
Amarin (NASDAQ: AMRN) highlights the role of VASCEPA (icosapent ethyl) in treating severe hypertriglyceridemia (sHTG) amid new injectable APOC3 therapies. VASCEPA delivers a 33% median TG reduction, broad cardiovascular risk reduction, and guideline support, with an annual WAC of about $4,200 versus $40,000 for some injectables.
Amarin (NASDAQ: AMRN) reported new post hoc data from the REDUCE-IT placebo arm at the 2026 European Atherosclerosis Society Congress. In 3,485 statin-treated patients with elevated triglycerides followed for 4.9 years, risk-weighted apoB (RW-apoB) averaged about 30% higher than measured apoB and more effectively identified residual cardiovascular risk than LDL-C, non-HDL-C, or apoB.
Applying ESC intervention thresholds, RW-apoB classified more patients as high risk, suggesting potential value for improved risk stratification in routine care.